

## **RESULTS OF ANNUAL GENERAL MEETING**

Bluechiip Limited (**Bluechiip** or the **Company**) (**ASX: BCT**), a leader in the development of advanced sample management solutions for harsh environments, is pleased to announce the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of a poll. In respect to Resolution 1 "Adoption of Remuneration Report", the resolution passed, in excess of 75% votes in favour of the resolution.

**END.**

**Authorised for release by the Bluechiip Limited Board**

For more information, please contact:

### **Corporate enquiries**

Andrew McLellan  
Managing Director / CEO  
Ph: +61 457 823 470  
[andrew.mclellan@bluechiip.com](mailto:andrew.mclellan@bluechiip.com)

### **Media**

Richard Allen  
Ph: +61 403 493 049  
Oxygen Financial PR  
[richard@oxygenpr.com.au](mailto:richard@oxygenpr.com.au)

### **About Bluechiip Limited**

Bluechiip understands that every biological sample – stem cells, blood, eggs, sperm and other biospecimens – is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced sample management solution is the only one that provides sample temperature with ID in cryogenic environments, driving productivity and improving quality. Bluechiip's solution delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product is easily identified and critical information, such as sample temperature, detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip<sup>®</sup> Advanced Sample

management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip listed on the ASX in June 2011. Since then, we have significantly developed our technology. Today it has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

**Bluechiip: Delivering confidence in every sample.**

Further information is available at [www.bluechiip.com](http://www.bluechiip.com)

For personal use only

# Disclosure of Proxy Votes

Bluechiip Limited

Annual General Meeting 2023

Thursday, 30 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	30,730,170	20,915,073 68.06%	2,249,005 7.32%	34,103,860	7,566,092 24.62%	32,683,140 93.56%	2,249,005 6.44%	34,157,194	Passed
2 Re-election of Andrew Cox as Director	P	96,419,463	87,713,971 90.97%	1,069,400 1.11%	396,672	7,636,092 7.92%	115,326,987 99.08%	1,069,400 0.92%	450,006	Passed
3 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	96,140,735	83,430,002 86.78%	5,074,641 5.28%	675,400	7,636,092 7.94%	111,043,018 95.63%	5,074,641 4.37%	728,734	Passed
4 Approval of Issue of Performance Rights to Andrew McLellan, CEO and Managing Director	P	64,704,030	46,693,754 72.17%	10,444,184 16.14%	130,000	7,566,092 11.69%	58,461,821 84.84%	10,444,184 15.16%	183,334	Passed
5 Approval of Issue of Shares to Related Party, Iain Kirkwood, Non-Executive Chair pursuant to the May Private Placement	P	84,743,352	75,284,527 88.84%	1,822,733 2.15%	0	7,636,092 9.01%	87,122,594 97.95%	1,822,733 2.05%	53,334	Passed
6 Approval of Issue of Shares to Related Party, Iain Kirkwood, Non-Executive Chair pursuant to the October Private Placement	P	84,743,352	75,284,527 88.84%	1,822,733 2.15%	0	7,636,092 9.01%	87,122,594 97.95%	1,822,733 2.05%	53,334	Passed
7 Approval of Issue of Shares to Related Party, Andrew McLellan, CEO and Managing Director pursuant to the October Private Placement	P	86,954,548	77,495,723 89.12%	1,822,733 2.10%	0	7,636,092 8.78%	105,108,739 98.30%	1,822,733 1.70%	53,334	Passed
8 Approval of Issue of Shares to Related Party, Michael Ohanessian, Non-Executive Director pursuant to the October Private Placement	P	86,663,000	72,449,099 83.60%	6,577,809 7.59%	105,400	7,636,092 8.81%	100,062,115 93.83%	6,577,809 6.17%	158,734	Passed

For personal use only



For personal use only

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Ratification of Prior Issue of 84,000,000 Shares Pursuant to a Private Placement	P	92,165,659	82,961,834 90.01%	1,567,733 1.70%	190,000	7,636,092 8.29%	110,574,850 98.60%	1,567,733 1.40%	243,334	Passed
10 Ratification of Prior Issue of 73,417,615 Shares Pursuant to a Private Placement	P	81,554,286	72,350,461 88.71%	1,567,733 1.92%	190,000	7,636,092 9.36%	99,963,477 98.46%	1,567,733 1.54%	243,334	Passed

